Not Yet RecruitingPhase 3Phase 4ACTRN12612000834853

Multi-tasking and acute Bacopa Monnieri (CDRI 08) supplementation

The effects of multi-tasking upon stress reactivity in healthy adults: an acute, double-blind, placebo controlled crossover study of 320mg and 640mg doses of a special extract of Bacopa monnieri (CDRI08).

Sponsor

Swinburne University of Technology

Enrollment

50 participants

Start Date

Aug 15, 2012

Study Type

Interventional

Conditions

Cognitive Function Stress

Summary

The aim of this study is to ascertain whether a standard clinical dose of 320 mg or a 640 mg dose of a specific extract of Bacopa Monnieri [KeenMind (Registered Trademark) - CDRI 08] would acutely affect cognition, mood, anxiety and stress at an earlier timepoint than previous Bacopa Monnieri supplementation studies. This study will investigate the cognitive and stress effects of a two doses of bacopa compared to placebo. Participants will be required to consume one of three treatments on each testing day, and will consume the other treatments on the other two days of testing. There will be a seven day washout period and the process will be repeated again. (1) Bacopa – 320mg (2) Bacopa – 640mg (3) Placebo

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 44 Yearss

Inclusion Criteria2

Non-smoker
Age between 18 and 44 years

Exclusion Criteria9

Not taking any medication, herbal extracts, vitamin supplements or illicit drugs
Not pregnant or lactating
Participants must abstain from caffeine-containing foods/beverages and alcohol for 24 hours prior to the training session and each testing session.
Written informed consent obtained
Smoker
History of psychiatric disorders or neurological diseases
Suffering from endocrine, gastrointestinal or bleeding disorders
Taking any medication, herbal extracts, vitamin supplements or illicit drugs
Pregnant or lactating

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

On each testing day, participants consume four capsules containing an inert placebo, 320mg of KeenMind(Registered Trademark) (CDRI 08) Bacopa Monnieri (BM) extract or 640mg of KeenMind (Registered Trademark) (CDRI 08) BM extract. KeenMind (Registered Trademark) (CDRI 08) is standardized for no less than 55% of total bacosides. Each capsule contains 160 mg BM extract (25:1) equivalent to 4 g of dried herb. Each participant is required to attend a total of 4 sessions (1 practice visit and 3 study visits) that will be conducted one week apart to ensure sufficient washout between each acute condition. Total amount of testing days is 4 weeks (inclusive of practice visit). There will be three separate testing days where either the placebo, 320 mg of KeenMind (Registered Trademark) or 640 mg of KeenMind (Registered Trademark) will be taken exclusively each day.